Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Zoetis Inc. is a global animal health company focused on the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostics, and related technologies for animals. The company operates within the animal health and veterinary pharmaceuticals industry, serving both livestock and companion animal markets. Zoetis generates revenue primarily from pharmaceutical products, vaccines, diagnostics, and genetic testing solutions that support animal health, productivity, and disease prevention.
Originally part of Pfizer Inc.’s animal health division, Zoetis was established as an independent company following an initial public offering in 2013 and a full separation later that year. Since becoming independent, Zoetis has expanded its product portfolio, strengthened its research and development capabilities, and built a leading position in global animal health, with a strategic emphasis on innovation, scale, and close relationships with veterinarians and livestock producers.
Business Operations
Zoetis operates through two primary business segments: Companion Animal and Livestock. The Companion Animal segment includes products for dogs, cats, and horses, such as parasiticides, vaccines, dermatology treatments, diagnostics, and pain management therapies, and represents the company’s largest and fastest-growing revenue contributor. The Livestock segment focuses on cattle, swine, poultry, fish, and sheep, offering vaccines, anti-infectives, medicated feed additives, and genetic technologies to enhance animal health and farm productivity.
The company maintains an integrated operating model that spans research and development, manufacturing, and commercial distribution. Zoetis controls a global manufacturing network and advanced R&D platforms, including biologics, small molecule pharmaceuticals, diagnostics, and data-driven genetic tools. Its operations are supported by a combination of wholly owned subsidiaries and long-term partnerships with veterinary distributors, diagnostic providers, and academic research institutions.
Strategic Position & Investments
Zoetis’s strategy centers on sustainable growth through innovation, lifecycle management of existing products, and targeted acquisitions that expand its technology base or market access. The company has made notable investments in diagnostics, digital technologies, and genetics to complement its pharmaceutical portfolio and deepen customer engagement. Acquisitions such as Abaxis, Inc. significantly strengthened Zoetis’s in-clinic diagnostics capabilities, while investments in genetic testing platforms enhanced its livestock precision agriculture offerings.
The company continues to allocate substantial resources to research and development, focusing on novel parasiticides, monoclonal antibodies, vaccines, and data-enabled solutions. Zoetis also emphasizes operational efficiency and disciplined capital allocation, balancing internal investment with shareholder returns through dividends and share repurchases.
Geographic Footprint
Zoetis operates in more than 100 countries, with major commercial and manufacturing operations across North America, Europe, Asia-Pacific, Latin America, and Africa. Its corporate headquarters are located in the United States, and the U.S. market represents its single largest source of revenue, particularly within the companion animal segment.
Internationally, Zoetis maintains a strong presence in developed and emerging markets, supported by localized manufacturing, R&D, and sales infrastructure. The company’s broad geographic footprint allows it to address region-specific animal health needs and regulatory environments while leveraging global scale and centralized innovation platforms.
Leadership & Governance
Zoetis is led by an experienced executive team with deep expertise in animal health, pharmaceuticals, and global operations. The leadership emphasizes a culture of innovation, customer-centricity, and ethical governance, with a strategic vision focused on advancing animal care while delivering long-term shareholder value.
Key executives include:
- Kristin Peck – Chief Executive Officer
- Wetteny Joseph – Executive Vice President and Chief Financial Officer
- Robert J. Smith – Executive Vice President, Global Manufacturing and Supply
- Michael McFarland – Executive Vice President and Chief Legal Officer
- Deanna F. Bass – Executive Vice President, Global Human Health and Talent